Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for several clinical situations where passive immunity against hepatitis B virus is required.

• Prevention of hepatitis B infection after known or suspected exposure to hepatitis B virus.
• Post‑exposure prophylaxis for individuals who have not completed the hepatitis B vaccine series or who have an inadequate vaccine response.
• Prevention of hepatitis B virus recurrence in patients undergoing liver transplantation.
• Supplementation of hepatitis B immune globulin in combination with active hepatitis B vaccination for high‑risk persons.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common

• Mild fever or chills during or shortly after infusion.
• Headache or dizziness.
• Nausea, vomiting, or abdominal discomfort.
• Local infusion site reactions such as erythema or swelling.

Serious

• Severe allergic reactions including anaphylaxis.
• Acute hemolytic transfusion reaction.
• Renal impairment or acute kidney injury.
• Thrombotic events such as deep‑vein thrombosis.

Before administering Hepatect Cp, clinicians should evaluate patient history and monitor for specific conditions that may increase risk.

• Assess for known hypersensitivity to human immunoglobulins or any component of the formulation.
• Evaluate renal function, especially in patients with pre‑existing kidney disease.
• Review cardiac status, as rapid infusion may affect circulatory volume.
• Consider the risk of thromboembolic events in individuals with clotting disorders or prolonged immobilization.
• Use caution in pregnant or breastfeeding women; safety data are limited.
• Verify hepatitis B serologic status to determine need for immunoglobulin therapy.

Hepatect Cp may interact with other medications or substances that influence immune response, coagulation, or renal function.

Avoid

• Concurrent administration of other blood products or immunoglobulins without appropriate monitoring.
• Use with live vaccines, as passive antibodies may interfere with vaccine efficacy.
• Simultaneous infusion of nephrotoxic drugs that could exacerbate renal impairment.

Use with caution

• Anticoagulants or antiplatelet agents, due to potential additive bleeding risk.
• Diuretics, which may affect intravascular volume during infusion.
• Cytotoxic chemotherapy agents, because of overlapping immunosuppressive effects.